PE20152003A1 - Reduccion del riesgo de la enfermedad autoinmune - Google Patents

Reduccion del riesgo de la enfermedad autoinmune

Info

Publication number
PE20152003A1
PE20152003A1 PE2015001891A PE2015001891A PE20152003A1 PE 20152003 A1 PE20152003 A1 PE 20152003A1 PE 2015001891 A PE2015001891 A PE 2015001891A PE 2015001891 A PE2015001891 A PE 2015001891A PE 20152003 A1 PE20152003 A1 PE 20152003A1
Authority
PE
Peru
Prior art keywords
related diseases
risk
nutritional composition
reducing
autoimmune disease
Prior art date
Application number
PE2015001891A
Other languages
English (en)
Inventor
Gabriele Gross
Dirk Hondmann
Tol Erick A F Van
Marieke H Schoemaker
Teartse Tim Lambers
Original Assignee
Mjn Us Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mjn Us Holdings Llc filed Critical Mjn Us Holdings Llc
Publication of PE20152003A1 publication Critical patent/PE20152003A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION SE REFIERE A UNA COMPOSICION NUTRICIONAL QUE COMPRENDE PEPTIDOS SELECIONADOS A PARTIR DE UN HIDROLIZADO DE CASEINA, QUE ADEMAS COMPRENDE UNA FASE DE GRASA O LIPIDO, Y UNA FUENTE DE PROTEINA. DE PREFERENCIA, EL HIDROLIZADO CONSISTE EN PEPTIDOS CON UN PESO MOLECULAR DE MAS DE 500 Da. ADICIONALMENTE, DICHA COMPOSICION COMPRENDE UNO O MAS DE HIDRATOS DE CARBONO, ACIDOS NUCLEICOS, LIPIDOS, MINERALES, NUTRIENTES ANABOLICOS, VITAMINAS, ANTIOXIDANTES, CEPAS BACTERIANAS PROBIOTICAS Y AGENTES LIPOTROPICOS. LA COMPOSICION NUTRICIONAL DE LA INVENCION ES UTIL PARA REDUCIR EL RIESGO DE ENFERMEDADES AUTOINMUNES TALES COMO DIABETES TIPO 1, ENFERMEDAD DE CROHN, COLITIS ULCEROSA, SINDROME METABOLICO, ENFERMEDADES RELACIONADAS CON HLA-DQ8, ENFERMEDADES RELACIONADAS CON HLA-DQ2, Y ENFERMEDAD CELIACA
PE2015001891A 2013-03-15 2014-03-11 Reduccion del riesgo de la enfermedad autoinmune PE20152003A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/839,212 US9289461B2 (en) 2013-03-15 2013-03-15 Reducing the risk of autoimmune disease

Publications (1)

Publication Number Publication Date
PE20152003A1 true PE20152003A1 (es) 2016-01-29

Family

ID=50483516

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001891A PE20152003A1 (es) 2013-03-15 2014-03-11 Reduccion del riesgo de la enfermedad autoinmune

Country Status (15)

Country Link
US (1) US9289461B2 (es)
EP (1) EP2968438A1 (es)
CN (1) CN105073126A (es)
AR (1) AR095335A1 (es)
AU (1) AU2014237022A1 (es)
BR (1) BR112015017909A2 (es)
CA (1) CA2905817A1 (es)
HK (1) HK1216994A1 (es)
MX (1) MX2015011927A (es)
PE (1) PE20152003A1 (es)
PH (1) PH12015502100B1 (es)
RU (1) RU2015139557A (es)
SG (1) SG11201505692QA (es)
TW (1) TW201521756A (es)
WO (1) WO2014150566A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10251928B2 (en) 2014-11-06 2019-04-09 Mead Johnson Nutrition Company Nutritional supplements containing a peptide component and uses thereof
US20170020950A1 (en) * 2015-07-23 2017-01-26 Mead Johnson Nutrition Company Methods for modulating kinases
CN109152790A (zh) 2016-05-11 2019-01-04 南加利福尼亚大学 禁食模仿膳食作为胃肠自身免疫性/炎性疾病的免疫调节治疗剂
EP3533451B1 (en) 2017-01-21 2022-07-27 Guangzhou Hanfang Pharmaceuticals Co., Ltd. Application of paeoniflorin-6'-o-benzene sulfonate in medicine for treating sjögren's syndrome
CN117384270B (zh) * 2023-10-13 2024-07-16 华南理工大学 一种酪蛋白源dpp-iv抑制六肽及其制备方法与应用

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2064092C2 (de) 1970-12-28 1983-06-01 Bayer Ag, 5090 Leverkusen Inhibitoren für Glykosidhydrolasen aus Actinomyceten
US3937817A (en) 1973-02-28 1976-02-10 Bayer Aktiengesellschaft Pharmaceutical compositions containing a saccharase inhibitor
US4016260A (en) 1974-07-22 1977-04-05 Toyama Chemical Co., Ltd. Novel polypeptide produced by pseudomonas
FR2474828B1 (fr) 1980-02-01 1983-09-09 Agronomique Inst Nat Rech Procede de traitement d'une matiere premiere a base de caseine, contenant des phosphocaseinates de cations bivalents, produits obtenus et application
FR2474829B1 (fr) 1980-02-01 1983-09-09 Agronomique Inst Nat Rech Procede de traitement d'une matiere a base de caseine contenant des phosphocaseinates de cations monovalents ou leurs derives, produits obtenus et applications
US4491589A (en) 1982-05-17 1985-01-01 The Trustees Of Columbia University In The City Of New York Amino acid solutions for parenteral nutrition and methods of formulation and use
DK589785A (da) 1985-12-18 1987-06-19 Samuelsson Ernst Gunnar Peptidpraeparat, fremgangsmaade til fremstilling deraf samt anvendelse af peptidpraeparatet
IT1190349B (it) 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
FR2608050B1 (fr) 1986-12-15 1990-04-13 Bellon Labor Sa Roger Procede de preparation d'un melange peptidique riche en di- et tri-peptides, utilisable notamment en nutrition artificielle et en dietetique, melange ainsi obtenu, et utilisation de ce melange en nutrition artificielle et en dietetique
US5230902A (en) 1988-04-29 1993-07-27 Immunotec Research Corporation Undenatured whey protein concentrate to improve active systemic humoral immune response
US5102871A (en) 1989-04-24 1992-04-07 Kyowa Hakko Kogyo Co., Ltd. Nutrient composition
FI904074A0 (fi) 1989-08-28 1990-08-17 Milupa Ag Protein-, peptid- och aminosyrablandningar med optimerad aminosyrasammansaettning samt deras anvaendning foer framstaellning av naering foer prematur- och dibarn samt av tillsatser till modersmjoelk.
US5407957A (en) 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
PH30997A (en) 1990-03-12 1997-12-23 Ciba Geigy Antipathologenically effective compositions comprising lytic peptides and hydrolytic enzymes.
AU661297B2 (en) 1991-01-24 1995-07-20 Martek Corporation Microbial oil mixtures and uses thereof
US5308832A (en) 1992-07-27 1994-05-03 Abbott Laboratories Nutritional product for persons having a neurological injury
GB9310472D0 (en) 1993-05-20 1993-07-07 Univ Warwick Phenylalanine-free protein and dna coding thereof
GB9312369D0 (en) 1993-06-16 1993-07-28 Sandoz Nutrition Ltd Organic compounds
US5405637A (en) * 1993-06-30 1995-04-11 Bristol-Myers Squibb Company Milk protein partial hydrolysate and infant formula containing same
US5723446A (en) 1993-12-23 1998-03-03 Nestec Ltd. Enteral formulation designed for optimized nutrient absorption and wound healing
US5714472A (en) 1993-12-23 1998-02-03 Nestec Ltd. Enternal formulation designed for optimized nutrient absorption and wound healing
US5605893A (en) 1994-03-15 1997-02-25 Children's Hospital Of Los Angeles Method of using a therapeutic food composition to diminish blood sugar fluctuations in diabetic patients
US5643880A (en) 1994-05-26 1997-07-01 Abbott Laboratories Product for inhibition of attachment of H. influenzae to human cells
DE69536000D1 (de) 1994-11-04 2009-10-22 A2 Corp Ltd Selektionsverfahren für nicht-diabetogene milch oder milchprodukte sowie hierdurch erfasste milch oder milchprodukte
US5821217A (en) 1995-10-27 1998-10-13 Beth Israel Deaconess Medical Center, Inc. Enteral formulation: low in fat and containing protein hydrolysates
IT1277964B1 (it) 1995-12-27 1997-11-12 Biosistema Di Pier Luigi Spara Prodotto derivato da latte, sostanzialmente esente da betacaseina di mammifero non umano e relativo uso
KR100194074B1 (ko) 1996-02-21 1999-06-15 박종헌 글루텐 펩타이드를 유효성분으로 포함하는 미네랄 흡수 촉진제
CA2260892A1 (en) 1996-07-17 1998-01-22 Nicada, Inc. Appetite suppression
KR100221124B1 (ko) 1996-09-23 1999-10-01 한상기 신규한 카제인 및 그 제조방법
NL1005037C2 (nl) 1997-01-17 1998-07-20 Nl Zuivelonderzoek Inst Werkwijze voor het selectief afbreken van melkeiwit, in het bijzonder voor het selectief hydrolyseren van caseïne/caseïnaat in aanwezigheid van andere melkeiwitten, in het bijzonder wei-eiwitten.
CA2340223A1 (en) 1998-08-12 2000-02-24 Morinaga Milk Industry Co., Ltd. Nutritional compositions for preventing or treating hyperlipoproteinemia
JP2000063284A (ja) * 1998-08-21 2000-02-29 Terumo Corp 炎症性腸疾患再燃防止剤
US6077558A (en) 1998-12-23 2000-06-20 Bristol-Myers Squibb Company Elemental nutritional products
US6905702B1 (en) 1999-11-08 2005-06-14 Children's Hospital Los Angeles Methods for regulating blood glucose and appetite suppression in type 2 diabetics
GB9927603D0 (en) 1999-11-22 2000-01-19 Nestle Sa Use of a milk protein hydrolysate in the treatment of diabetes
DE69930464D1 (de) 1999-12-30 2006-05-11 Kerry Group Services Ltd Aufbaupräparat, das Kohlenhydrat- und Peptidmaterial enthält und sein Gebrauch als Energieergänzung nach oder während körperlicher Übung oder als metabolischer Nährstoff für die orale Verabreichung
NL1014380C2 (nl) 2000-02-14 2001-08-15 Friesland Brands Bv Darmwandversterkend voedingsmiddel.
US6207638B1 (en) 2000-02-23 2001-03-27 Pacifichealth Laboratories, Inc. Nutritional intervention composition for enhancing and extending satiety
IL134830A0 (en) 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
US7666996B2 (en) 2000-03-01 2010-02-23 Peptera Pharmaceuticals Ltd Casein derived peptides and uses thereof
TWI268138B (en) 2000-05-11 2006-12-11 Kanebo Seiyaku Ltd Composition containing peptide and electrolyte excretion enhancing substance, and food containing the same
EP1298204B1 (en) 2000-06-28 2007-04-04 Fuji Nihon Seito Corporation Novel inulin synthase and process for producing inulin by using the same
GB0016189D0 (en) 2000-06-30 2000-08-23 Pepsyn Ltd Cosmetic composition
WO2002019832A1 (en) 2000-09-08 2002-03-14 New Zealand Dairy Board MILK CONTAINING β-CASEIN WITH PROLINE AT POSITION 67 DOES NOT AGGRAVATE NEUROLOGICAL DISORDERS
AU1142001A (en) 2000-10-19 2002-04-29 Dsm N.V. Protein hydrolysates
WO2003005836A2 (en) 2001-07-10 2003-01-23 Trustees Of Boston University Modified-fat nutritional products useful for preventing or treating obesity
ATE372689T1 (de) 2001-07-18 2007-09-15 Dsm Ip Assets Bv Verfahren zur hydrolyse von milcheiweissen
DE10149668A1 (de) 2001-10-09 2003-04-10 Numico Res B V Insulinmimetische Aminosäuresequenzen
JP2003137804A (ja) 2001-10-31 2003-05-14 Morinaga Milk Ind Co Ltd インターロイキン−１８誘導剤
PT1457498E (pt) 2001-11-21 2007-05-31 Morinaga Milk Industry Co Ltd Novo péptido possuindo efeito inibitório da convertase da angiotensina.
EP1359157A1 (en) 2002-04-29 2003-11-05 Société des Produits Nestlé S.A. Metallo-proteinase inhibitory agent
US7460960B2 (en) 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
EP1509609B1 (en) 2002-06-04 2015-04-22 DSM IP Assets B.V. Protein hydrolysate rich in tripeptides
FR2841473B1 (fr) 2002-06-27 2004-09-17 Ingredia Utilisation d'au moins un peptide de la caseine s2 a activite inhbitrice de l'enzyme de conversion de l'engiotensine i pour la preparation de medicaments, d'aliments et de complements alimentaires
EP1534314B1 (en) 2002-09-04 2014-10-22 DSM IP Assets B.V. A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
TWI317636B (en) 2002-11-22 2009-12-01 Meiji Dairies Corp Nutritional compositions for liver disease patients or for patients underhigh levels of invasive stress
US20050148504A1 (en) 2002-11-29 2005-07-07 Nobuhiko Katunuma Cysteine protease inhibitor
EP2141235B1 (en) 2002-12-29 2014-06-11 Toudai Tlo, Ltd. Adiponectin receptor and gene coding for the same
WO2004098309A1 (en) 2003-05-05 2004-11-18 Unilever N.V. Hydrolysed casein product comprising tripeptides ipp and/ or vpp
EP1663298B1 (en) 2003-09-23 2019-07-17 DSM IP Assets B.V. Use of proline specific endoproteases to hydrolyse peptides and proteins
JP4943853B2 (ja) 2003-10-24 2012-05-30 エヌ．ブイ．・ヌートリシア 免疫調節性オリゴ糖
BE1015863A6 (nl) 2004-01-19 2005-10-04 Huybrechts Lucas Anticariogene proteinen & peptiden & sacchariden.
AU2005207891B2 (en) 2004-01-28 2010-04-01 Andromeda Biotech Ltd. Hsp therapy in conjunction with a low antigenicity diet
EP1568707A1 (en) 2004-02-26 2005-08-31 Puleva Biotech, S.A. Antihypertensive peptides from casein hydrolysates
KR20070007128A (ko) 2004-03-01 2007-01-12 펩테라 파마슈티컬스 엘티디. 카제인 파생 펩타이드들과 그의 치료적 사용들
KR20070034528A (ko) 2004-05-27 2007-03-28 캄피나 네덜란드 홀딩 베.붸. Ｄｐｐ－ｉｖ 매개 질병의 예방 및／또는 치료용 의약품제조를 위한 단백질 가수분해물의 용도
DE102004040452A1 (de) 2004-08-20 2006-02-23 N.V. Nutricia Peptidgemisch
KR100560127B1 (ko) 2004-09-04 2006-03-13 한국기초과학지원연구원 인산화 단백질 분석용 겔-내 표지화 및 겔-내 단리 방법및 이를 이용한 단백질의 인산화 위치 동정 방법
US20080108548A1 (en) 2004-11-12 2008-05-08 N.V. Nutricia Food Composition For Rapidly Attenuating Inflammatory Responses
WO2006068480A2 (en) 2004-12-23 2006-06-29 Campina Nederland Holding B.V. Protein hydrolysate enriched in peptides inhibiting dpp-iv and their use
ATE491349T1 (de) 2005-01-18 2011-01-15 Dsm Ip Assets Bv Neue nutrazeutika-zusammensetzungen
DE602006011275D1 (de) 2005-02-03 2010-02-04 Dsm Ip Assets Bv Zusammensetzungen mit epigallocatechingallat und proteinhydrolysat
DE602006005788D1 (de) 2005-02-09 2009-04-30 Unilever Nv Lebensmittelprodukte mit hydrolysierten milchfeststoffen mit verbessertem geschmack
WO2006114194A1 (en) 2005-04-28 2006-11-02 Unilever N.V. Peptides having a health benefit and compositions comprising them
EA200702352A1 (ru) 2005-04-28 2008-02-28 ДСМ АйПи АССЕТС Б.В. Новые композиции нутрицевтиков
EP1874327A1 (en) 2005-04-29 2008-01-09 Campina Nederland Holding B.V. Antiviral peptides
ES2319475B1 (es) 2005-06-08 2010-02-16 Consejo Superior Investig. Cientificas Peptidos bioactivos identificados en hidrolizados enzimaticos de caseinas lacteas y procedimiento de obtencion.
US20090203592A1 (en) 2005-07-01 2009-08-13 N.V. Nutricia Infant nutrition with hydrolised proteins
GB0523806D0 (en) 2005-11-23 2006-01-04 Micromass Ltd Mass spectrometer
JP2009517464A (ja) 2005-11-30 2009-04-30 カンピーナ ネーダーランド ホールディング ビー．ブイ． グルカゴン様ペプチド１の活性を増強するタンパク質加水分解物の使用
WO2008054192A1 (en) 2006-11-02 2008-05-08 N.V. Nutricia Use of nutritional compositions for preventing disorders
ATE509624T1 (de) 2005-12-23 2011-06-15 Nutricia Nv Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz
US20100167979A1 (en) 2006-02-09 2010-07-01 Calpis Co. Ltd Rheumatoid arthritis-preventive agent for oral intake
WO2007107587A2 (en) 2006-03-22 2007-09-27 Dsm Ip Assets B.V. Cholesterol lowering protein hydrolysates
CN101420867A (zh) 2006-04-12 2009-04-29 帝斯曼知识产权资产管理有限公司 新颖的营养药物组合物
JP5645360B2 (ja) 2006-04-21 2014-12-24 株式会社明治 ジペプチドを有効成分として含有する組成物
US8207131B2 (en) 2006-04-28 2012-06-26 Megmilk Snow Brand Co., Ltd. Peptide
KR20080003637A (ko) 2006-07-03 2008-01-08 한상기 다이어트효과가 우수한 기능성 유산균발효조성물
DK2164349T3 (en) 2006-08-04 2014-12-15 Shs Int Ltd protein-FORMULA
US8642736B2 (en) 2006-08-09 2014-02-04 Dsm Ip Assets B. V. Casein complexes
NL1032840C2 (nl) 2006-11-09 2008-05-13 Friesland Brands Bv Probiotische hydrolysaatvoeding voor kinderen.
NL1033521C2 (nl) 2007-03-08 2008-09-09 Friesland Brands Bv Kindervoedingen met geoptimaliseerde aminozuursamenstelling.
BRPI0811857A2 (pt) 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
CA2688293A1 (en) 2007-05-25 2008-12-04 Childrens's Medical Center Corporation Dietary formulations and methods for treatment of inflammation and other disorders
WO2008153429A2 (en) 2007-06-11 2008-12-18 Uniwersytet Jagiellonski A protease from staphylococcus aureus, particularly spia or spib, peptides it recognises and their use
EP2187955A2 (en) 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Therapeutic use of peptide yglf and combination with kvlpvpq
WO2009054435A1 (ja) 2007-10-24 2009-04-30 Otsuka Chemical Co., Ltd. 増強されたエフェクター機能を有するポリペプチド
WO2009138762A2 (en) * 2008-05-15 2009-11-19 Regen Therapeutics Plc Therapeutic use of peptides
US8859210B2 (en) 2008-10-17 2014-10-14 Mead Johnson Nutrition Company Method for identifying allergenic proteins and peptides
JP5735734B2 (ja) 2009-04-16 2015-06-17 雪印メグミルク株式会社 脂質代謝改善剤
EP2253324A1 (en) 2009-04-30 2010-11-24 Consejo Superior De Investigaciones Cientificas Use of a casein-derived peptide and compositions thereof as antihypertensive
EP2295535A1 (en) 2009-09-11 2011-03-16 Mead Johnson Nutrition Company Probiotic material
EP2332428B1 (en) 2009-12-04 2014-08-20 MJN U.S. Holdings LLC Nutritional Formulation comprising a cow's milk peptide-containing hydrolysate and/or peptides derived thereof for tolerance induction
EP2525811B2 (en) 2010-01-19 2019-02-27 Abbott Laboratories A composition comprising lactobacillus rhamnosus hn001 and prebiotics for use in the treatment of allergic lung disease
EP2540308A1 (en) 2010-02-24 2013-01-02 Morinaga Milk Industry Co., Ltd. Therapeutic agent for eating disorders
EP2514435A1 (en) 2011-04-19 2012-10-24 Nestec S.A. Infant formula for use in the prevention of cardiovascular diseases

Also Published As

Publication number Publication date
BR112015017909A2 (pt) 2017-11-21
EP2968438A1 (en) 2016-01-20
TW201521756A (zh) 2015-06-16
MX2015011927A (es) 2015-12-01
SG11201505692QA (en) 2015-08-28
RU2015139557A (ru) 2017-05-02
HK1216994A1 (zh) 2016-12-16
PH12015502100A1 (en) 2016-01-18
AU2014237022A1 (en) 2015-08-13
WO2014150566A1 (en) 2014-09-25
CN105073126A (zh) 2015-11-18
CA2905817A1 (en) 2014-09-25
US20140274892A1 (en) 2014-09-18
AR095335A1 (es) 2015-10-07
US9289461B2 (en) 2016-03-22
PH12015502100B1 (en) 2016-01-18

Similar Documents

Publication Publication Date Title
PE20152003A1 (es) Reduccion del riesgo de la enfermedad autoinmune
EA201790378A1 (ru) Заключенное в липосому аффинное лекарственное средство
PE20151765A1 (es) Formulas a base de hidrolizado de aminoacido y proteina con un sistema estable de emulsion
BR112012031183A2 (pt) líquidos nutricionais substancialmente claros compreendendo proteína de cálcio hmb e solúvel
BR112017014580A8 (pt) Método para obter um isolado peptídico a partir de uma biomassa de microalgas enriquecidas com proteína
PH12016500705A1 (en) Calcitonin mimetics for treating diseases and disorders
UY35548A (es) Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
BR112016027871A2 (pt) composição para melhorar a memória, a função de aprendizado e/ou função cognitiva
CL2011003003A1 (es) Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria.
ECSP17043318A (es) Composición que contiene quitina y proteínas digeribles
AR111589A1 (es) Enzimas lactasas con propiedades mejoradas
UY35740A (es) Análogos de amilina
CR20170197A (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidópteros
BR112015025733A2 (pt) composição compreendendo uma combinação de um ex-trato de sabugueiro e uma estirpe de lactobacillus rhamnosus
BR112016011489A2 (pt) composição nutricional pediátrica com peptídeos do leite para crescimento e desenvolvimento saudável
BR112015027540A2 (pt) ácido graxo de resina líquida
BR112015009344A2 (pt) produto nutricional líquido com hmb, alto teor de proteína e baixa viscosidade
PE20150190A1 (es) Formulacion farmaceutica
BR112015005933A2 (pt) composição nutricional para mulher grávida com um perfil benéfico de glicose e insulina
TW201613631A (en) Ghrelin secretion promoter
CL2015003803A1 (es) Osteopontina lactea de mamifero para mejorar la capacidad de respuesta inmunitaria.
AR095661A1 (es) Método de activación de adiponectina mediante hidrolizado de caseína
AR099344A1 (es) Composición nutricional que comprende suero y caseína hidrolizada
PH12017500740A1 (en) Nutritional supplements containing a peptide component and uses thereof
MX2015014450A (es) Cepa de lactobacillus rhamnosus para regular el metabolismo de lipidos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal